Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate

Communications & Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 15, 2014 Organovo Holdings, Inc. (NYSE ... on delivering breakthrough 3D bioprinting technology,  today celebrated ... of its exVive3D TM Human Liver Tissue.  ... full commercial release on November 18, has been ... several awards for innovation. Most recently, ...
(Date:12/13/2014)... CHARLOTTE, N.C. (PRWEB) December 13, 2014 ... (UNC Charlotte) spin-out company has changed its name to ... more accurate representation of where we are today,” said ... “We’ve extended our platform’s applications beyond breast cancer diagnostics ... is a reflection of that evolution.” , Founded in ...
(Date:12/13/2014)... and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... less rosy indicators in overall global economic growth, Eugene ... optics and photonics , said in a featured talk ... on 5 December at the National Chung Hsing University ... which is being integrated into future energy supplies and ...
(Date:12/13/2014)... AUSTIN, Texas , Dec. 12, 2014  Vermillion, ... disease, announced today the appointments of Veronica G. ... to the Company,s Board of Directors, bringing the ... are independent. Jim LaFrance , ... "I am tremendously pleased to announce the appointments of ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3
... Corporation (NYSE: KMB ) today announced ... Global Nonwovens, has been named to Savoy Magazine,s ... The Top 100 listing showcases a cross section ... a diverse range of industries who demonstrate leadership and ...
... engineer Robert J. Wood has been named one of ... T. Waterman Award. Wood, an Associate Professor of ... Applied Sciences (SEAS) and a Core Member of the ... the honor with Scott Aaronson of the Massachusetts Institute ...
... 2012  On the occasion of World Kidney Day, Kibow ... from an expanded clinical trial of Renadyl™ ( http://www.Renadyl.com ... quality of life (QOL) previously established in a pilot-scale ... in the product formulation are "Generally Recognized As Safe" ...
Cached Biology Technology:Kimberly-Clark's Bob Stargel Named One of Savoy Magazine's Top 100 Most Influential Blacks in Corporate America 2Kimberly-Clark's Bob Stargel Named One of Savoy Magazine's Top 100 Most Influential Blacks in Corporate America 3Engineer Robert J. Wood to receive NSF's Alan T. Waterman Award 2Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function 2Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function 3
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... pollen next, you have to literally think like one. , ... are more likely to stick with it rather than invest ... student at the University of Wisconsin-Milwaukee (UWM). , Flanigan ... bees as they gather pollen ?which plant species the bees ...
... five-year, $1 million grant from the National Cancer Institute, a ... improve the effectiveness of a drug that he developed ... Waldemar Debinski, M.D., Ph.D., pioneered a method to destroy cells ... The drug is currently being tested in clinical trials and ...
... research team led by scientists at the Broad Institute of ... kind of genetic "roadmap" that can connect human diseases with ... new drugs work in human cells. Called the "Connectivity Map," ... September 29 issue of Science and in separate publications in ...
Cached Biology News:Researchers find that bumblebees' flower choice matters 2Researchers find that bumblebees' flower choice matters 3Researchers find that bumblebees' flower choice matters 4Scientist works to improve treatment for brain tumors 2Genetic 'roadmap' charts links between drugs and human disease 2Genetic 'roadmap' charts links between drugs and human disease 3
... induced prior to DNA purification increasing DNA ... single-copy BACs with the high yields associated ... kits provide the linearized vector and associated ... necessary to create a 10X human BAC ...
Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
... EPICENTREs patented MasterAmp™ 10X PCR ... performance and allows improved sensitivity and ... templates. Using MasterAmp™ PCR Enhancer in ... of DNA melting, increases enzyme?s thermal ...
Biology Products: